Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Summit Therapeutics Inc. is one of them.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company focused on oncology, developing therapies for non-small cell lung cancer (NSCLC) and other unmet medical needs. Its lead investigational drug, ivonescimab, targets EGFR-mutated NSCLC patients, particularly those who have progressed after third-generation EGFR tyrosine kinase inhibitors (TKIs).

In September 2025, SMMT provided updates on ivonescimab’s Phase III HARMONi trial during the World Conference on Lung Cancer (WCLC 2025). The trial evaluates ivonescimab combined with platinum-doublet chemotherapy versus chemotherapy plus placebo in advanced or metastatic non-squamous NSCLC patients with EGFR mutations. Top-line results released in May 2025 showed a statistically significant improvement in progression-free survival, with positive trends in overall survival, although not statistically significant.

Ivonescimab is already approved for first-line treatment in China for PD-L1-positive advanced NSCLC, marking a key commercial milestone. Summit Therapeutics Inc. (NASDAQ:SMMT) continues to expand clinical programs with ongoing HARMONi-3 and HARMONi-7 Phase III trials, including enrollment in the U.S., signaling a strategic push for broader regulatory approvals and global market adoption.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.